| (Values in U.S. Thousands) | Dec, 2022 | Dec, 2021 | Dec, 2020 | Mar, 2026 | Mar, 2026 |
| Sales | 580 | 7,800 | 1,620 | 0 | 0 |
| Sales Growth | -92.56% | +381.48% | unch | unch | unch |
| Net Income | -91,760 | -66,970 | -18,850 | 0 | 0 |
| Net Income Growth | -37.02% | -255.28% | unch | unch | unch |
Icosavax Inc (ICVX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Icosavax Inc. is a biopharmaceutical company which focuses on life-threatening respiratory diseases. The company's virus-like particle platform technology involved in developing vaccines against infectious diseases. Icosavax Inc. is based in SEATTLE.
Fiscal Year End Date: 12/31